Repligen Corporation $RGEN Position Raised by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. increased its stake in Repligen Corporation by 1.3%, acquiring an additional 13,284 shares, bringing its total ownership to approximately 1.82% valued at $130.3 million.
• Repligen reported $182.37 million in revenue for the last quarter, exceeding analyst estimates, although it missed EPS expectations with a reported $0.37 against a consensus of $0.40.
• Analysts currently hold a consensus rating of "Moderate Buy" on Repligen's stock, with price targets averaging around $169.55, despite recent downgrades by some brokerages.

Alliancebernstein L.P. boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,024,180 shares of the biotechnology company's stock after acquiring an additional 13,284 shares during the period. Alliancebernstein L.P. owned about 1.82% of Repligen worth $130,317,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 Asset Management L.P. raised its holdings in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares in the last quarter. Nuveen LLC bought a new position in Repligen during the first quarter worth $35,536,000. Artemis Investment Management LLP raised its stake in Repligen by 110.1% during the 1st quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock valued at $41,128,000 after acquiring an additional 169,397 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Repligen by 17,721.1% during the first quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company's stock worth $15,510,000 after acquiring an additional 121,212 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of Repligen stock traded up $3.98 during trading on Friday, hitting $124.56. 1,043,994 shares of the company's stock traded hands, compared to its average volume of 674,243. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market capitalization of $7.01 billion, a P/E ratio of -498.22, a PEG ratio of 2.29 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The business has a 50-day simple moving average of $121.53 and a 200-day simple moving average of $129.06.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company's revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Tuesday. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $169.55.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.